# US 2019/0194396 A1 · Novel plga-modified polyethylenimine self-assembly nanotechnology for nucleic acid and drug delivery

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0194396 A1
- Document ID: US20190194396A1
- Status: Published application
- Kind: A1
- Application number: 16/296,925
- Filed: 2019-03-08
- Published: 2019-06-27
- Earliest claimed: 2013-08-13
- Assignees: Baylor College of Medicine
- Applicants: Baylor College of Medicine
- Inventors: Jian-Ming Lu; Qizhi Yao; Changyi Chen
- Web page: https://patentgrep.com/patent/US20190194396A1

## CPC

- C08G 81/00: Macromolecular compounds obtained by interreacting polymers in the absence of monomers, e.g. block polymers (involving only carbon-to-carbon unsaturated bond reactions C08F299/00 {; polyester-amides C08G69/44; polyester-imides C08G73/16; polyamides-imides C08G73/14; block- or graft polymers containing polysiloxane sequences C08G77/42})
- A61K 47/59: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K 47/593: {Polyesters, e.g. PLGA or polylactide-co-glycolide}
- A61K 47/60: the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61K 47/6935: {the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol}
- A61K 47/6937: {the polymer being PLGA, PLA or polyglycolic acid}
- A61K 48/0041: {the non-active part being polymeric}
- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61P 35/00: Antineoplastic agents
- C08G 63/6852: {derived from hydroxy carboxylic acids}
- C08G 63/912: {derived from hydroxycarboxylic acids}
- C08G 73/0206: {Polyalkylene(poly)amines}
- C08G 81/027: {containing polyester or polycarbonate sequences}
- C12N 15/88: using microencapsulation, e.g. using {amphiphile} liposome vesicle
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/32: Special delivery means, e.g. tissue-specific
- C08G: MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Embodiments of the invention concern copolymers and nanoparticles for use as delivery agents for one or more agents for therapy for a medical condition of humans and animals. Some of embodiments of the invention provide new reagents for biomedical research in cell culture, animal models and plants, for example. The copolymers comprise PLGA and PEI and, in some embodiments, also comprise 1-(3-aminopropyl)-4-methylpiperazine (APMP), Fc binding peptide and/or antibody. In certain embodiments, APMP-PLGA-PEI, Fc binding peptide/antibody-PLGA-PEI or Fc binding peptide/antibody-APMP-PLGA-PEI nanoparticles comprising one or more therapeutic agents are delivered to an individual in need thereof or used for biomedical research in cell cultures, animal models and plants.

## Claims

### Claim 1

A composition comprising:
a copolymer consisting of lactide-co-glycolide and PEI;
wherein single lactide-co-glycolide (LGA) units are each conjugated to primary amines of PEI through an amide linkage;
wherein the w/w ratio of LGA to PEI is 0.5:1 to 5:1; and
at least one therapeutic and/or diagnostic agent selected from the group consisting of a nucleic acid, protein, peptide, small molecule, antigen, vaccine, delivery agent, antibody, and mixtures thereof.

### Claim 2 (depends on 1)

The composition of claim 1, wherein the composition is in the form of a microparticle or a nanoparticle.

### Claim 3 (depends on 1)

The composition of claim 1, wherein the copolymer is chemically conjugated to a linker.

### Claim 4 (depends on 3)

The composition of claim 3, wherein the linker is a polyethylene glycol (PEG) linker.

### Claim 5 (depends on 4)

The composition of claim 4, wherein the PEG linker is Maleimide-PEG-NHS.

### Claim 6 (depends on 3)

The composition of claim 3, wherein the linker is chemically conjugated to Fc binding peptide or antibody for specific delivery.

### Claim 7 (depends on 1)

The composition of claim 1, wherein the nucleic acid is DNA.

### Claim 8 (depends on 7)

The composition of claim 7, wherein the DNA is double stranded, single stranded, or a mixture thereof.

### Claim 9 (depends on 7)

The composition of claim 7, wherein the DNA is an oligonucleotide.

### Claim 10 (depends on 1)

The composition of claim 1, wherein the nucleic acid is RNA.

### Claim 11 (depends on 10)

The composition of claim 10, wherein the RNA is double stranded, single stranded, or a mixture thereof.

### Claim 12 (depends on 10)

The composition of claim 10, wherein the RNA is an oligonucleotide.

### Claim 13 (depends on 10)

The composition of claim 10, wherein the RNA is siRNA, shRNA, miRNA, or a mixture thereof.

### Claim 14 (depends on 1)

The composition of claim 1, wherein the composition is a controlled or sustained release composition.

### Claim 15 (depends on 1)

The composition of claim 1, wherein the diagnostic agent is a labeled diagnostic agent.

### Claim 16

A composition comprising:
a copolymer consisting of lactide-co-glycolide, PEI, and one compound selected from the group consisting of 1-β-aminopropyl)-4-methylpiperazine (APMP), 2-(3-aminopropylamino) ethanol, 2-methyl-1,5-diaminopentane, 1-(3-aminopropyl)pyrrolidine, 4-aminophenyl disulfide, and cystamine;
wherein single lactide-co-glycolide units are each conjugated to primary amines of PEI through an amide linkage;
wherein the w/w ratio of LGA to PEI is 0.5:1 to 5:1; and
at least one therapeutic and/or diagnostic agent selected from the group consisting of a nucleic acid, protein, peptide, small molecule, antigen, vaccine, delivery agent, antibody, and mixtures thereof.

### Claim 17 (depends on 16)

The composition of claim 16, wherein the composition is in the form of a microparticle or a nanoparticle.

### Claim 18

A method of making a composition comprising at least one therapeutic and/or diagnostic agent and a copolymer consisting of lactide-co-glycolide and PEI, the method comprising the steps of:
mixing PLGA and PEI in a solvent to provide a solution comprising a lactide-co-glycolide and PEI copolymer;
adding at least one therapeutic and/or diagnostic agent to the copolymer solution to provide a dispersion; and
isolating the composition comprising at least one therapeutic and/or diagnostic agent and copolymer.

### Claim 19 (depends on 18)

The method of claim 18, wherein the step of adding at least one therapeutic and/or diagnostic agent to the copolymer solution comprises conjugating the copolymer to a linker that is conjugated to the at least one therapeutic and/or diagnostic agent.

### Claim 20

A copolymer composition comprising
lactide-co-glycolide and PEI; and
optionally one compound selected from the group consisting of 1-β-aminopropyl)-4-methylpiperazine (APMP), 2-β-aminopropylamino) ethanol, 2-methyl-1,5-diaminopentane, 1-β-aminopropyl)pyrrolidine, 4-aminophenyl disulfide and cystamine;
wherein single lactide-co-glycolide units are each conjugated to primary amines of PEI through an amide linkage; and
wherein the w/w ratio of LGA to PEI is 0.5:1 to 5:1.
